H.B. No. 1802
  relating to a study on the use of alternative therapies for treating
  post-traumatic stress disorder.
         SECTION 1.  (a) In this Act, "commission" means the Health
  and Human Services Commission.
         (b)  The commission, in collaboration with Baylor College of
  Medicine and in partnership with a military veterans hospital or a
  medical center that provides medical care to veterans, shall
  conduct a study on the efficacy of using alternative therapies,
  including the use of 3,4-methylenedioxymethamphetamine (MDMA),
  psilocybin, and ketamine, in the treatment of veterans who suffer
  from post-traumatic stress disorder.
         (c)  In conducting the study described by Subsection (b) of
  this section, the commission in collaboration with the Baylor
  College of Medicine shall:
               (1)  perform a clinical trial on the therapeutic
  efficacy of using psilocybin in the treatment of
  treatment-resistant post-traumatic stress disorder in veterans;
               (2)  review current literature regarding:
                     (A)  the safety and efficacy of
  3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and
  ketamine in the treatment of post-traumatic stress disorder; and
                     (B)  the access veterans have to
  3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and
  ketamine for treatment of post-traumatic stress disorder in the
  United States.
         (d)  The commission shall prepare and submit to the governor,
  the lieutenant governor, the speaker of the house of
  representatives, and each member of the legislature:
               (1)  quarterly reports on the progress of the study
  conducted under this section; and
               (2)  not later than December 1, 2024, a written report
  containing the results of the study conducted under this section
  and any recommendations for legislative or other action.
         (e)  The commission shall ensure any protected health
  information collected during a clinical trial conducted under
  Subsection (c) of this section and reported under Subsection (d) of
  this section does not personally identify an individual.
         (f)  This Act expires September 1, 2025.
         SECTION 2.  The Agency is required to implement this Act only
  if the legislature appropriates money specifically for that
  purpose. If the legislature does not appropriate money
  specifically for that purpose, the commission may, but is not
  required to, implement this Act using other appropriations
  available for the purpose.
         SECTION 3.  This Act takes effect immediately if it receives
  a vote of two-thirds of all the members elected to each house, as
  provided by Section 39, Article III, Texas Constitution. If this
  Act does not receive the vote necessary for immediate effect, this
  Act takes effect September 1, 2021.
  ______________________________ ______________________________
     President of the Senate Speaker of the House     
         I certify that H.B. No. 1802 was passed by the House on May 6,
  2021, by the following vote:  Yeas 134, Nays 12, 1 present, not
  voting; and that the House concurred in Senate amendments to H.B.
  No. 1802 on May 28, 2021, by the following vote:  Yeas 134, Nays 9,
  2 present, not voting.
  Chief Clerk of the House   
         I certify that H.B. No. 1802 was passed by the Senate, with
  amendments, on May 22, 2021, by the following vote:  Yeas 25, Nays
  Secretary of the Senate   
  APPROVED: __________________